Thus, these findings extend the potential investigation of ATM to neurodevelopmental disorders and since, in neurons, DSB repair seems to specifically occur through the activation of the NPAS4–NuA4 complex, the pharmacological targeting of ATM in autism should not affect ability of neurons to repair DNA damages, as they are governed by completely different processes and protein repertoires. The gene discussed is NPAS4; the disease is neurodevelopmental disorder.